Natera (NTRA) Stock Rating Upgraded by Zacks Investment Research
According to Zacks, “Natera, Inc. offers genetic testing and diagnostics with proprietary bioinformatics and molecular technology. Natera, Inc. is headquartered in San Carlos, California. “
Several other analysts have also commented on NTRA. BidaskClub lowered Natera from a hold rating to a sell rating in a research note on Tuesday, April 16th. Canaccord Genuity reaffirmed a buy rating and issued a $25.00 price target on shares of Natera in a research note on Monday, March 11th. Finally, ValuEngine raised Natera from a buy rating to a strong-buy rating in a research note on Tuesday, January 15th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of Buy and a consensus price target of $28.00.
Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Tuesday, March 12th. The medical research company reported ($0.51) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.51). Natera had a negative return on equity of 790.13% and a negative net margin of 49.72%. The company had revenue of $67.00 million for the quarter, compared to analyst estimates of $62.87 million. Research analysts expect that Natera will post -2.24 EPS for the current year.
In other Natera news, insider Matthew Rabinowitz sold 5,672 shares of the business’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $16.00, for a total value of $90,752.00. Following the transaction, the insider now owns 1,288,853 shares of the company’s stock, valued at $20,621,648. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Jonathan Sheena sold 23,356 shares of the business’s stock in a transaction on Wednesday, March 13th. The stock was sold at an average price of $20.51, for a total value of $479,031.56. Following the completion of the transaction, the insider now directly owns 294,758 shares in the company, valued at approximately $6,045,486.58. The disclosure for this sale can be found here. In the last three months, insiders sold 351,313 shares of company stock worth $7,132,873. Insiders own 13.18% of the company’s stock.
A number of institutional investors have recently bought and sold shares of the business. State Board of Administration of Florida Retirement System boosted its stake in Natera by 6.7% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 11,485 shares of the medical research company’s stock worth $160,000 after purchasing an additional 717 shares in the last quarter. Legal & General Group Plc boosted its stake in Natera by 14.5% in the fourth quarter. Legal & General Group Plc now owns 5,826 shares of the medical research company’s stock worth $81,000 after purchasing an additional 736 shares in the last quarter. Alliancebernstein L.P. boosted its stake in Natera by 7.3% in the third quarter. Alliancebernstein L.P. now owns 41,000 shares of the medical research company’s stock worth $982,000 after purchasing an additional 2,800 shares in the last quarter. Brandywine Managers LLC boosted its stake in Natera by 12.9% in the fourth quarter. Brandywine Managers LLC now owns 26,200 shares of the medical research company’s stock worth $366,000 after purchasing an additional 3,000 shares in the last quarter. Finally, Wells Fargo & Company MN boosted its stake in Natera by 6.9% in the third quarter. Wells Fargo & Company MN now owns 52,899 shares of the medical research company’s stock worth $1,266,000 after purchasing an additional 3,411 shares in the last quarter. 87.76% of the stock is currently owned by institutional investors.
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
See Also: How Does the Quiet Period Work?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.